Immunotoxin-Based Targeted Therapy for Cancer, CCR4 Bispecific
Summary
The USPTO published patent application US20260098097A1 for methods of treating cancer using a genetically engineered C-C motif chemokine receptor 4 (CCR4) bispecific immunotoxin. The application, filed December 29, 2023, covers treatment of cutaneous T-cell lymphoma and other cancers via administration of the immunotoxin alone or in combination with additional therapeutic agents such as antibody-drug conjugates.
What changed
The USPTO published patent application US20260098097A1 disclosing methods of treating various cancers, including cutaneous T-cell lymphoma, using a genetically engineered CCR4 bispecific immunotoxin pharmaceutical composition. The application claims treatment methods involving administering the immunotoxin alone or in combination with additional therapeutic agents such as antibody-drug conjugates.
For biotechnology and pharmaceutical companies developing immunotoxin-based cancer therapeutics, this published application establishes prior art and may affect freedom-to-operate assessments. Competitors pursuing similar CCR4-targeted bispecific immunotoxin approaches should evaluate the scope of the disclosed claims and consider filing divisional or continuation applications to protect alternative embodiments not covered by this filing.
What to do next
- Monitor for updates on patent prosecution status
- Review claims for competitive implications if developing similar immunotoxin therapeutics
Archived snapshot
Apr 10, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
IMMUNOTOXIN-BASED TARGETED THERAPY FOR CANCER
Application US20260098097A1 Kind: A1 Apr 09, 2026
Inventors
Zhirui Wang, Zhaohui Wang, Bradley Haverkos
Abstract
Methods of treating various types of cancer, including cutaneous T-cell lymphoma, involve administering a therapeutically effective amount of a pharmaceutical composition containing a genetically engineered C-C motif chemokine receptor 4 bispecific immunotoxin, alone, or in combination with one or more additional therapeutic agents, such as a pharmaceutical composition containing an antibody-drug conjugate.
CPC Classifications
C07K 16/2866 A61K 39/3955 A61K 47/68031 A61K 47/6849 A61P 35/00 C07K 14/55 A61K 2039/505 C07K 2317/622 C07K 2317/73 C07K 2317/92 C07K 2319/55
Filing Date
2023-12-29
Application No.
19140326
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.